Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1997 3
1999 1
2000 6
2001 17
2002 23
2003 27
2004 43
2005 47
2006 49
2007 54
2008 74
2009 91
2010 91
2011 105
2012 103
2013 102
2014 108
2015 77
2016 75
2017 65
2018 56
2019 38
2020 39
2021 52
2022 38
2023 9
Text availability
Article attribute
Article type
Publication date

Search Results

1,216 results
Results by year
Filters applied: . Clear all
Page 1
[Olmesartan-associated Enteropathy].
Zou L, Wang Q, Li Y, Yang AM. Zou L, et al. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2021 Dec 30;43(6):986-990. doi: 10.3881/j.issn.1000-503X.13268. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2021. PMID: 34980342 Review. Chinese.
Olmesartan,an angiotensin receptor blocker,is a commonly used antihypertensive drug.Several case reports and cohort studies in recent years have described a severe gastrointestinal adverse event with chronic diarrhea,intestinal malabsorption,and weight loss after the admin …
Olmesartan,an angiotensin receptor blocker,is a commonly used antihypertensive drug.Several case reports and cohort studies in recent …
Efficacy of sacubitril/valsartan versus olmesartan in Japanese patients with essential hypertension: a randomized, double-blind, multicenter study.
Rakugi H, Kario K, Yamaguchi M, Sasajima T, Gotou H, Zhang J. Rakugi H, et al. Hypertens Res. 2022 May;45(5):824-833. doi: 10.1038/s41440-021-00819-7. Epub 2022 Jan 21. Hypertens Res. 2022. PMID: 35058583 Free PMC article. Clinical Trial.

Greater reductions in msSBP with sacubitril/valsartan 400 mg vs. olmesartan, as well as in msDBP and msPP with both doses of sacubitril/valsartan vs. olmesartan (P < 0.05 for all), were also observed. ...The safety and tolerability profiles of sacubitril/valsarta

…
Greater reductions in msSBP with sacubitril/valsartan 400 mg vs. olmesartan, as well as in msDBP and msPP with both doses of sacubitr …
Efficacy and safety of sacubitril/valsartan compared with olmesartan in Asian patients with essential hypertension: A randomized, double-blind, 8-week study.
Huo Y, Li W, Webb R, Zhao L, Wang Q, Guo W. Huo Y, et al. J Clin Hypertens (Greenwich). 2019 Jan;21(1):67-76. doi: 10.1111/jch.13437. Epub 2018 Dec 11. J Clin Hypertens (Greenwich). 2019. PMID: 30536595 Free PMC article. Clinical Trial.
The primary endpoint was reduction in mean sitting systolic blood pressure (msSBP) from baseline with sacubitril/valsartan 200 mg vs olmesartan 20 mg at Week 8. Secondary endpoints included msSBP reduction with sacubitril/valsartan 400 mg, and reductions in clinic and ambu …
The primary endpoint was reduction in mean sitting systolic blood pressure (msSBP) from baseline with sacubitril/valsartan 200 mg vs olme …
Olmesartan.
Al-Majed AA, Bakheit AHH, Abdel Aziz HA, Al-Jallal AAM. Al-Majed AA, et al. Profiles Drug Subst Excip Relat Methodol. 2017;42:241-286. doi: 10.1016/bs.podrm.2017.02.005. Epub 2017 Mar 31. Profiles Drug Subst Excip Relat Methodol. 2017. PMID: 28431778
Olmesartan is an angiotensin receptor blockers with actions similar to those of losartan; it is used for the treatment of high blood pressure by relaxing blood vessels for this reason blood can flow more easily. ...Comprehensive pharmacology is also presented (pharm …
Olmesartan is an angiotensin receptor blockers with actions similar to those of losartan; it is used for the treatment of high blood …
Effects of Sacubitril/Valsartan Versus Olmesartan on Central Hemodynamics in the Elderly With Systolic Hypertension: The PARAMETER Study.
Williams B, Cockcroft JR, Kario K, Zappe DH, Brunel PC, Wang Q, Guo W. Williams B, et al. Hypertension. 2017 Mar;69(3):411-420. doi: 10.1161/HYPERTENSIONAHA.116.08556. Epub 2017 Jan 16. Hypertension. 2017. PMID: 28093466 Clinical Trial.
Patients (n=454; mean age, 67.7 years; mean seated systolic blood pressure, 158.6 mm Hg; mean seated pulse pressure, 69.7 mm Hg) were randomized to receive once-daily sacubitril/valsartan 200 mg or olmesartan 20 mg, force titrated to double the initial doses after 4 weeks, …
Patients (n=454; mean age, 67.7 years; mean seated systolic blood pressure, 158.6 mm Hg; mean seated pulse pressure, 69.7 mm Hg) were random …
Olmesartan-induced enteropathy.
Onteddu NK, Pulivarthi VSKK, Ginnavaram M, Kedika R. Onteddu NK, et al. BMJ Case Rep. 2018 Oct 2;2018:bcr2018224411. doi: 10.1136/bcr-2018-224411. BMJ Case Rep. 2018. PMID: 30279248 Free PMC article.
Olmesartan-induced enteropathy (OIE) typically presents with a constellation of signs and symptoms including chronic diarrhoea, weight loss and villous atrophy on biopsy. ...This report serves as an addition to existing literature and to increase the awareness of olmesa …
Olmesartan-induced enteropathy (OIE) typically presents with a constellation of signs and symptoms including chronic diarrhoea, weigh …
Olmesartan-Induced Enteropathy.
Adike A, Corral J, Rybnicek D, Sussman D, Shah S, Quigley E. Adike A, et al. Methodist Debakey Cardiovasc J. 2016 Oct-Dec;12(4):230-232. doi: 10.14797/mdcj-12-4-230. Methodist Debakey Cardiovasc J. 2016. PMID: 28289500 Free PMC article.
Olmesartan-induced enteropathy mimics celiac disease clinically and pathologically. As in celiac disease, the pathologic findings are villous atrophy and increased intraepithelial lymphocytes. Clinical presentation of olmesartan-induced enteropathy includes diarrhea …
Olmesartan-induced enteropathy mimics celiac disease clinically and pathologically. As in celiac disease, the pathologic findings are …
Olmesartan-associated enteropathy: Belgian survey.
Allaoui A, Marcoux D, Vokaer B, Couturier B. Allaoui A, et al. Therapie. 2021 Jan-Feb;76(1):58-60. doi: 10.1016/j.therap.2020.02.023. Epub 2020 Mar 29. Therapie. 2021. PMID: 32284216 No abstract available.
Olmesartan-induced enteropathy: More than one entity?
Famularo G, Aglitti A, Magrini L. Famularo G, et al. Eur J Intern Med. 2022 Nov;105:113. doi: 10.1016/j.ejim.2022.06.025. Epub 2022 Jul 5. Eur J Intern Med. 2022. PMID: 35798591 No abstract available.
Gastrointestinal: Olmesartan-induced enteropathy.
Shahzad MA, Harding D, Ruszkiewicz A, Tran E, England G, Philpott H. Shahzad MA, et al. J Gastroenterol Hepatol. 2018 Oct;33(10):1691. doi: 10.1111/jgh.14317. Epub 2018 Jul 2. J Gastroenterol Hepatol. 2018. PMID: 29968297 No abstract available.
1,216 results